CYTK vs FOLD vs RARE vs KRYS vs ACAD

For growth investors, Cytokinetics, Incorporated (CYTK) is the stronger pick with 376.

6% revenue growth year-over-year, versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Cytokinetics, Incorporated (CYTK) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 8x versus Krystal Biotech, Inc. at 44. 7x. On forward P/E, Krystal Biotech, Inc. is actually cheaper at 39. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +364. 0%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: KRYS returned +27. 7% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 61β versus Ultragenyx Pharmaceutical Inc. 's 1. 36β — meaning RARE is approximately 123% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Krystal Biotech, Inc. (KRYS) carries a lower debt/equity ratio of 1% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cytokinetics, Incorporated (CYTK) is pulling ahead at 376.

6% versus 11. 9% for ACADIA Pharmaceuticals Inc. (ACAD). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -24. 3% for Cytokinetics, Incorporated. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -891. 6% for Cytokinetics, Incorporated — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -695. 4% for CYTK. At the gross margin level — before operating expenses — KRYS leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Krystal Biotech, Inc.

(KRYS) trades at 39. 4x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 16. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RARE: 85. 1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cytokinetics, Incorporated (CYTK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80), +849. 5% 10Y return). Both have compounded well over 10 years (CYTK: +849. 5%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the null sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CYTK is a small-cap high-growth stock; FOLD is a small-cap high-growth stock; RARE is a small-cap high-growth stock; KRYS is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.